ArticleFrontiers in immunology2026
Immune checkpoint inhibitor-related thyroid dysfunction during treatment of lung cancer: a disproportionality analysis based on the FDA adverse event reporting system.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immune checkpoint inhibitors (ICIs) have exhibited remarkable clinical benefits in the treatment of lung cancer, yet a large-scale pharmacovigilance investigation on ICI-related thyroid dysfunction (ICI-TD) remained limited. This study aimed to comprehensively analyze the demographic characteristics of ICI-TD in lung cancer patients and the pharmacovigilance signal patterns of the adverse events (AEs) using data from the Food and Drug Administration Adverse Event Reporting System (FAERS) database. Methods: All existing data ranging from January 1 Results: A total of 2,001 reports of ICI-TD during treatment of lung cancer were identified after data processing, involving 1,758 patients and 10 ICIs. In general, ICI-TD were mainly reported in male patients (n = 959, 54.55%) and patients aged ≥ 65 years (n = 856, 48.69%; median [lower quartile (Q1), upper quartile (Q3)] = 67 [60, 73]). After data cleaning, we found that reports from 752 patients had valid time-to-onset (TTO) values. The median TTO of ICI-TD was 42 days [Q1, Q3] = [14, 98], and ICI-TD was predominantly reported within 30 days after ICI administration (n = 323, 42.95% of all 752 patients). The vast majority of patients were reported as having serious reaction outcome (n = 1,690, 96.13%). Among all ICIs, nivolumab had the greatest number of ICI-TD reports (a = 655, 32.73% of all 2,001 reports, ROR Conclusions: The present study provided a comprehensive overview of the demographic features of patients and pharmacovigilance signal patterns of ICI-TD during the treatment of lung cancer. Our findings would offer a referential perspective for the clinical understanding of the pharmacovigilance signals of ICI-TD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.